Aradigm Corporation Completes Enrollment in Phase 2 Study of Inhaled Liposomal Ciprofloxacin for Bronchiectasis

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (“Aradigm”) today announced it completed enrollment in its Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.